- Overview of HCC in veterans
- Improvement in treatment options for HCC and the impact of a collaborative approach
- Treating locally advanced, inoperable HCC
- Initial systemic therapy options for advanced, unresectable HCC
- Optimal treatment sequence following disease progression after initial therapy
- Best practices for collaborative clinical decision making and key factors into incorporating new agents into clinical practice for HCC at all stages of disease
David Kaplan, MD, MSc
Perelman School of Medicine
University of Pennsylvania
Director of Hepatology
Corporal Michael J. Crescenz VA Medical Center
The goal of this activity is to improve participants’ knowledge and competence of regarding the management of patients with hepatocellular carcinoma.
This program is intended for physicians, nurses, and other healthcare providers who care for patients with hepatocellular carcinoma.
- Select first-line treatment for individual patients with unresectable HCC, considering the available clinical evidence, known agent toxicity/tolerability profiles, expert recommendations, and patient preferences
- Apply clinical evidence and expert recommendations to select optimal treatment for patients with progressive hepatocellular carcinoma after 1 or multiple previous lines of therapy
- Recall the biologic rationale for and available clinical data with checkpoint inhibition in the treatment of HCC
- Plan therapeutic strategies that optimize the sequence of therapies to provide the best outcome to patients with HCC
- Counsel patients to understand their treatment options and to be proactive, knowledgeable participants in their care
- Employ effective collaborative strategies to ensure optimal application of the latest HCC treatment approaches
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.